Guardant Health to appeal Delaware patent ruling by TwinStrand

Guardant Health (Nasdaq: GH) announced it will appeal a final judgment from the U.S. District Court for the District of Delaware related to intellectual property claims brought by TwinStrand Biosciences, Inc. and the University of Washington. Execution of the judgment and collection of potential royalties will be stayed pending the appeal.

The court order, which defined the scope of royalties based on products that existed at the time of the 2023 trial, excludes current versions of Guardant's Reveal and Shield products, as many earlier versions have since been discontinued or upgraded. Guardant also stated it has validated design improvements to its Guardant360 product and related services that would exclude the impact of potential ongoing royalties under the ruling.

"We strongly disagree with this decision and will promptly be appealing for its overturn," said John Saia, Guardant Health Chief Legal Officer. "We have full faith in the strengths and merits of Guardant's intellectual property and R&D and are confident we will ultimately prevail on appeal."

Guardant said both TwinStrand patents have been preliminarily invalidated in ongoing challenges before the U.S. Patent and Trademark Office. The company is also pursuing separate appeals before the U.S. Court of Appeals for the Federal Circuit.

You May Also Be Interested In

• Canaccord Starts BillionToOne Inc (BLLN) at Buy
• Increasing unusual call option volume: GPRO FHN ITB DPRO EIX FRVO SLB PSNL OLLI CRK PCG
• Active options: AMD PFE PLTR SOFI GOOGL PBR MSTR HOOD SNDK MRVL